TING THERAPEUTICS LLC
Omaha, NE · Biotech · Private
CDK2 inhibitor small molecule drug (TT001) to prevent cisplatin-induced hearing loss
tingtherapeutics.com →- Grants
- $7.7M
- 19 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 14
- 5 granted · 9 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · CDK2 inhibitors for protecting hearing loss | $220,653 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · CDK2 inhibitors for protecting hearing loss | $220,653 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutics to prevent cisplatin-induced hearing loss by transcriptomics | $205,736 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutics to prevent cisplatin-induced hearing loss by transcriptomics | $205,736 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Therapeutics to prevent aminoglycoside-induced hearing loss | $242,322 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Therapeutics to prevent aminoglycoside-induced hearing loss | $242,322 | |
| Federal grant | Department of Health and Human Services · Phase II · CDK2 inhibitors for protecting hearing loss | $566,238 | |
| Federal grant | Department of Health and Human Services · Phase II · CDK2 inhibitors for protecting hearing loss | $1,107,570 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical evaluation of an otoprotectant TT002 | $621,419 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical evaluation of an otoprotectant TT002 | $1,187,190 | |
| Federal grant | Department of Health and Human Services · Phase II · CDK2 inhibitors for protecting hearing loss | $541,332 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical evaluation of an otoprotectant TT002 | $565,771 | |
| Federal grant | Department of Health and Human Services · Phase II · CDK2 inhibitors for protecting hearing loss | $176,763 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Preclinical evaluation of an otoprotectant TT002 | $1 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Therapeutics to prevent aminoglycoside-induced hearing loss | $1 | |
| Federal grant | Department of Health and Human Services · Phase II · Therapeutics to prevent aminoglycoside-induced hearing loss | $524,299 | |
| Federal grant | Department of Health and Human Services · Phase II · CDK2 inhibitors for protecting hearing loss | $174,684 | |
| Federal grant | Department of Health and Human Services · Phase II · Preclinical evaluation of an otoprotectant TT002 | $326,371 | |
| Federal grant | Department of Health and Human Services · Phase II · Therapeutics to prevent aminoglycoside-induced hearing loss | $524,300 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1309 | COARE BIOTECHNOLOGY, INC. | — | — |
| 1310 | Pinnacle Medicines | — | — |
| 1311 | Riptide Bioscience, Inc. | — | — |
| 1312 | TING THERAPEUTICS LLC | — | — |
| 1313 | Kodikaz Therapeutic Solutions, Inc. | — | — |
| 1314 | THERATARGET, INC. | — | — |
| 1315 | OAKGROVE BIO LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compositions and Methods for the Prevention and Treatment of Hearing Lossgranted
- Methods for the Prevention and Treatment of Hearing Loss using Oseltamivirgranted
- Methods for the Prevention and Treatment of Hearing Lossgranted
- Methods for the Prevention and Treatment of Hearing Lossgranted
- Compositions and Methods for the Prevention and Treatment of Hearing Lossgranted
- Methods For The Prevention And Treatment Of Hearing Lossapplication
- Methods For The Prevention And Treatment Of Hearing Lossapplication
- Methods For The Prevention And Treatment Of Hearing Lossapplication
- Composition and Methods for the Prevention of Aminoglycoside Toxicityapplication
- Compositions And Methods For The Prevention And Treatment Of Hearing Lossapplication
- Methods for the Prevention and Treatment of Hearing Lossapplication
- Methods for the Prevention and Treatment of Hearing Lossapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.